Medicare AdvantageJune 1, 2022
Medical policies and clinical utilization Management guidelines update
The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.
Please share this notice with other members of your practice and office staff.
To view a guideline, visit https://www.anthem.com/ca/provider/policies/clinical-guidelines.
Notes/updates:
Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive:
- *CG-LAB-20 — Thyroid Testing:
- Outlines the Medically Necessary and Not Medically Necessary criteria for thyroid testing.
- *CG-LAB-21 — Serum Iron Testing:
- Outlines the Medically Necessary and Not Medically Necessary criteria for serum iron testing.
- *LAB.00043 — Immune Biomarker Tests for Cancer:
- Oncologic immune biomarker tests are considered Investigational and Not Medically Necessary for all indications.
- *LAB.00044 — Saliva-Based Testing to Determine Drug-Metabolizer Status:
- Saliva-based testing to determine drug-metabolizer status is considered Investigational and Not Medically Necessary for all indications.
- *LAB.00045 — Selected Tests for the Evaluation and Management of Infertility:
- The following tests or procedures are considered Investigational and Not Medically Necessary for diagnosing or managing infertility:
- Endometrial receptivity analysis
- Sperm-capacitation test
- Sperm deoxyribonucleic acid (DNA) fragmentation test
- Sperm penetration assay
- Uterine natural killer (uNK) cells test
- *LAB.00046 — Testing for Biochemical Markers for Alzheimer’s Disease:
- Measurements of biochemical markers (including but not limited to tau protein, AB-42, neural thread protein) is considered Investigational and Not Medically Necessary as a diagnostic technique for individuals with symptoms suggestive of Alzheimer’s disease.
- Measurements of biochemical markers as a screening technique in asymptomatic individuals with or without a family history of Alzheimer’s disease is considered Investigational and Not Medically Necessary.
- Moved content related to biomarker testing for Alzheimer’s disease from GENE.00003 Biochemical Markers for the Diagnosis and Screening of Alzheimer’s Disease to this document.
- *RAD.00067 — Quantitative Ultrasound for Tissue Characterization:
- Quantitative ultrasound for tissue characterization is considered Investigational and Not Medically Necessary for all indications.
- *SURG.00154 — Microsurgical Procedures for the Prevention or Treatment of Lymphedema:
- Revised Position Statement to include the prevention of lymphedema.
- *SURG.00160 — Implanted Port Delivery Systems to Treat Ocular Disease:
- The use of a port delivery system to treat ocular disease is considered Investigational and Not Medically Necessary for all indications.
- *TRANS.00038 — Thymus Tissue Transplantation:
- Outlines the Medically Necessary and Investigational and Not Medically Necessary criteria for allogeneic processed thymus tissue.
Medical Policies
On February 17, 2022, the Medical Policy, and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem Blue Cross (Anthem). These guidelines take effect June 4, 2022.
Publish date |
Medical Policy number |
Medical Policy title |
New or revised |
04/13/2022 |
*LAB.00043 |
Immune Biomarker Tests for Cancer |
New |
04/13/2022 |
*LAB.00044 |
Saliva-based Testing to Determine Drug-Metabolizer Status |
New |
04/13/2022 |
*LAB.00045 |
Selected Tests for the Evaluation and Management of Infertility |
New |
04/13/2022 |
*LAB.00046 |
Testing for Biochemical Markers for Alzheimer’s Disease |
New |
04/13/2022 |
*RAD.00067 |
Quantitative Ultrasound for Tissue Characterization |
New |
04/13/2022 |
*SURG.00160 |
Implanted Port Delivery Systems to Treat Ocular Disease |
New |
03/25/2022 |
*TRANS.00038 |
Thymus Tissue Transplantation |
New |
04/13/2022 |
GENE.00052 |
Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling |
Revised |
04/1/2022 |
SURG.00011 |
Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting |
Revised |
02/24/2022 |
SURG.00036 |
Fetal Surgery for Prenatally Diagnosed Malformations |
Revised |
04/13/2022 |
SURG.00096 |
Surgical and Ablative Treatments for Chronic Headaches |
Revised |
04/13/2022 |
*SURG.00154 |
Microsurgical Procedures for the Prevention or Treatment of Lymphedema |
Revised |
Clinical UM Guidelines
On February 17, 2022, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines adopted by the medical operations committee for our members on
March 24, 2022. These guidelines take effect June 4, 2022.
Publish date |
Clinical UM Guideline number |
Clinical UM Guideline title |
New or Revised |
04/13/2022 |
*CG-LAB-20 |
Thyroid Testing |
New |
04/13/2022 |
*CG-LAB-21 |
Serum Iron Testing |
New |
04/13/2022 |
CG-ANC-03 |
Acupuncture |
Revised |
04/13/2022 |
CG-GENE-14 |
Gene Mutation Testing for Cancer Susceptibility and Management |
Revised |
04/13/2022 |
CG-MED-73 |
Hyperbaric Oxygen Therapy (Systemic/Topical) |
Revised |
04/13/2022 |
CG-SURG-36 |
Adenoidectomy |
Revised |
02/24/2022 |
CG-SURG-86 |
Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection |
Revised |
PUBLICATIONS: June 2022 Anthem Blue Cross Provider News - California
To view this article online:
Or scan this QR code with your phone